Acute Lymphoblastic Leukemia in Children.

@article{Hunger2015AcuteLL,
  title={Acute Lymphoblastic Leukemia in Children.},
  author={Stephen P. Hunger and Charles G. Mullighan},
  journal={The New England journal of medicine},
  year={2015},
  volume={373 16},
  pages={
          1541-52
        }
}
The most common cancer in childhood is now curable in 90% of patients. Current efforts are focused on devising molecular-based therapy for the subsets of acute lymphoblastic leukemia that are most resistant to current therapy. 
Resolving the Genomic Complexity of Pediatric Acute Lymphoblastic Leukemia
TLDR
A large number of children diagnosed with acute lymphoblastic leukemia in the Nordic countries have had at least one promoter mutation, which is a hallmark of ALL and represents key markers for diagnosis and treatment. Expand
Genomics in childhood acute myeloid leukemia comes of age
A Children's Oncology Group study of nearly 1,000 pediatric acute myeloid leukemia (AML) cases reveals marked differences between the genomic landscapes of pediatric and adult AML and offersExpand
Nationwide survey of pediatric hypodiploid acute lymphoblastic leukemia in Japan
Ploidy is a highly significant prognostic factor for pediatric acute lymphoblastic leukemia (ALL). Children with hypodiploid ALL have poor outcomes despite current intensive chemotherapy. Little hasExpand
Pediatric Acute Lymphoblastic Leukemia
TLDR
Therapy options, including chimeric antigen receptor (CAR)-T-cell therapies for pediatric acute lymphoblastic leukemia (ALL), are discussed in ONCOLOGY. Expand
High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah’s Witnesses patients: a feasible option in the age of hematopoietic growth factors
B-cell acute lymphoblastic leukemia (B-ALL) can be cured in most children and in the majority of young adults with sufficiently intensive – and myelosuppressive – combination chemotherapy regimens ...
CAR-T Cells: An Innovative Therapeutic Strategy Against Pediatric Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is a prevalent and highly progressive cancer in children and adolescents associated with an excessive production of immature lymphocytes in the bone marrow, whichExpand
Excellent outcome of acute lymphoblastic leukaemia with TCF3‐PBX1 rearrangement in Hong Kong
The aim of this study was to review clinical outcomes and prognosis of paediatric patients with acute lymphoblastic leukaemia (ALL) with TCF3‐PBX1 rearrangement.
Immunotherapy in Pediatric Acute Lymphoblastic Leukemia
TLDR
Treatment for patients with B-ALL remains a therapeutic challenge despite successes due to multi-agent chemotherapy regiments, CNS prophylaxis and better risk stratification. Expand
Molecular Biology of B- and T-ALL
Acute lymphoblastic leukemia (ALL) is traditionally classified into precursor B-, precursor T-, and B-cell (Burkitt) and then subclassified on the basis of recurrent cytogenetic changes that includeExpand
Thrombotic potential during pediatric acute lymphoblastic leukemia induction: Role of cell‐free DNA
Thromboembolism affects up to 30% of children undergoing treatment for acute lymphoblastic leukemia (ALL). Increased thrombin generation has been reported in ALL, but the mechanisms remain elusive.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 108 REFERENCES
Treatment of childhood acute lymphoblastic leukemia in central America: A lower‐middle income countries experience
Five Asociación de Hemato‐Oncología de Centroamérica (AHOPCA) countries have used an adapted BFM‐based protocol for childhood acute lymphoblastic leukemia (ALL).
A study of "total therapy" of acute lymphocytic leukemia in children.
TLDR
The intensive systemic administration of antileukemic agents resulted in longer complete remissions than described in other studies, and survival was at least equal to that obtained with sequential use of these agents. Expand
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.
TLDR
While relapse is the main contributor to poorer survival in DS-ALL, infection-associated TRM was increased in all protocol elements, unrelated to treatment phase or regimen. Expand
Molecular pathogenesis of T-cell leukaemia and lymphoma
TLDR
This Review focuses on the molecular mechanisms responsible for disease induction and maintenance in T-ALL and compares the physiological progression of T-cell differentiation with T- cell transformation, highlighting the close relationship between these two processes. Expand
Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia
TLDR
Improved risk stratification and chemotherapy have eliminated the previous independent prognostic significance of gender, CNS leukemia and translocation, whereas the post-induction level of minimal residual disease (MRD) has emerged as a new risk grouping feature. Expand
Adolescents and young adults with acute lymphoblastic leukemia.
  • W. Stock
  • Medicine
  • Hematology. American Society of Hematology. Education Program
  • 2010
TLDR
This review will describe current controversies surrounding the treatment of adolescents and young adults with ALL--a group who finds themselves in the transition from "pediatric" to "adult" treatment approaches. Expand
Trends in childhood cancer incidence in the U.S. (1992–2004)
TLDR
Examination of population‐based incidence data provides insight regarding etiology among various demographic groups and may result in new hypotheses, including Asian/Pacific Islanders and Hispanics, for whom to the authors' knowledge trends have not been previously examined. Expand
Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid.
TLDR
The occurrence of what the author interpreted as an "acceleration phenomenon" in the leukemic process as seen in the marrow and viscera of children with acute leukemia treated by the injection of folic acid conjugates1 and pteroyltriglutamic acid (teropterin) — and an experience gained from studies on folic . Expand
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.
  • S. Hunger, X. Lu, +5 authors W. Carroll
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
This study documents ongoing survival improvements for children and adolescents with acute lymphoblastic leukemia, emphasizing that efforts to further improve survival must be directed at both high-risk subsets and at those children predicted to have an excellent chance for cure. Expand
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia : Children ’ s Oncology Group Study AALL 0031
We previously reported preliminary findings that post induction imatinib mesylate (340 mg/m2/ day), in combination with intensive chemotherapy, resulted in outcomes similar to blood and marrowExpand
...
1
2
3
4
5
...